Early stage researchers, including Phase I clinics and units, which have limited resources, can now access the TrialOne Express designed for early-stage research.
T1xpress is a prefab eClinical solution for Phase I clinic automation and offers preset configurations that help researchers with limited resources to automate their facilities and launch clinical studies quickly.
Go deeper with GlobalData
The features include a pre-configured library, barcoded label templates, preset system roles and recruitment screens.
OmniComm Systems president and CEO Stephen Johnson said: “OmniComm’s TrialOne solution has been widely recognised as the most functionally robust Phase I clinic automation solution in the industry.
“However, the level of effort to implement such a robust solution and the hardware requirements necessary to host it have, in some cases, put it out of reach for some smaller Phase I clinics.
“This new prepackaged and fully hosted turnkey solution will allow for a much shorter implementation schedule, affording these smaller clinics all the benefits of a tier I solution at a much lower total cost of ownership.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataT1xpress also provides data capture, sample tracking, data exporting and Exago custom reporting hosted in the OmniCloud in three locations.
OmniComm’s package also includes standard process workflow diagrams, a validation starter kit and a ‘quick-start’ implementation schedule.
Last month, an international CRO signed an agreement to use OmniComm’s TrialMaster for future studies, including an upcoming Phase Ib study on behalf of a UK-based sponsor.
The company provides solutions for clinical research with a global experience from more than 6,000 clinical trials.
